

Atty Dkt. No.: UCAL-203 USSN: 09/828,505

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 1, 6, 8, 9, 11-13, 15-18, 19, 22, and 26 without prejudice to renewal. Please enter the amendments to claims 2-5, 7, 10, 14, 20, 21, 23-25, and 27-32, as shown bel Please enter new claim 33, as shown below.

1. (Canceled)

- 2. (Currently Amended) A polynucleotide composition comprising a nucleic acid encoding a plant allergen derived from a non-host species of a first phylum or first kingdom The polynucleotide vaccine of claim 1, wherein the nucleic acid sequence encoding the plant allergen antigen is further modified to include a signal sequence derived from a second phylum or second kingdom, wherein the signal sequence is operably linked to the allergen-encoding antigen-encoding sequence.
- 3. (Currently Amended) The polynucleotide composition vaccine of claim 2, wherein the signal sequence comprises a hemagglutinin A (HA) signal sequence.
- 4. (Currently Amended) The polynucleotide composition vaccine of claim 2 1, wherein at least one codon of the nucleic acid sequence encoding the plant allergen antigen is modified from a wild type sequence of the non-host species to an analogous codon of a host species.
- 5. (Currently Amended) The polynucleotide composition vaccine of claim 2 1, further comprising a universal antigen or an immunogenic fragment thereof.
 - 6. (Canceled)
- 7. (Currently Amended) The polynucleotide composition vaccine of claim 2 1, wherein the antigen is Amb a1.
 - 8-9. (Canceled)

Atty Dkt. No.: UCAL-203 USSN: 09/828,505

10. (Currently Amended) A method for modulating an reducing a Th2 immune response to a plant allergen, an antigen comprising administering to a subject an effective amount of a polynucleotide composition vaccine of claim 2 + and an effective amount of an immunostimulatory nucleotide sequence (ISS) comprising an unmethylated 5'-CG-3' nucleotide sequence in an amount effective to modulate an to reduce a Th2 immune response to the allergen antigen.

11-13. (Canceled)

14. (Currently Amended) The method of claim 10 13, wherein the plant allergen is ragweed or grass pollen.

15-19. (Canceled)

- 20. (Currently Amended) The method of claim 10 19, wherein the ISS comprises a sequence selected from the group consisting of: 5'-rrcgyy-3', 5'-rycgyy-3', 5'-rrcgyycg-3', 5'-rycgyycg-3' and or 5'-(TCG)n-3'.
- 21. (Currently Amended) The method of claim 20, wherein the sequence is <u>AACGTT</u> selected from the group consisting of: AACGTT, AGCGTT, GACGTT, GACGTT, GGCGTT, AACGTC, AGCGCC, GACGCC, GACGCC, GACGCC, AACGCT, AGCGCT, GACGCT, GGCGCT, ATCGTT, ACCGTT, GTCGTT, GCCGTT, ATCGTC, ACCGTC, GTCGTC, GCCGTC, ATCGCT, ACCGCT, GTCGCT, GCCGCT, ATCGCC, ACCGCC, GTCGCC, GCCGCC, AACGTTCG, GACGTTCG, GACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, AACGTCCG, AACGCTCG, AACGCCCG, AACGCCCG, AACGCTCG, AACGCTCG, AACGCTCG, AACGCTCG, ATCGTTCG, ACCGTTCG, GCCGTTCG, ATCGTCCG, ACCGTCCG, AACGCTCG, ATCGTTCG, ACCGTTCG, GCCGTTCG, ATCGTCCG, ACCGCCCG, GTCGCCCG, GTCGCCCG, ATCGCTCG, ACCGCTCG, ATCGCTCG, ACCGCTCG, GTCGCCCG, ATCGCTCG, ACCGCTCG, ACCGCTCG, ACCGCCCG, GTCGCCCG, ATCGCTCG.

22. (Canceled)

Atty Dkt. No.: UCAL-203 USSN: 09/828.505

23. (Currently Amended) A polynucleotid composition comprising a nucleic acid encoding an Amb a1 allergen modified by deletion of a native Amb a1 signal sequence. The polynucleotide vaccine of claim 22, wherein the nucleic acid sequence encoding the Amb a1 allergen is further modified to comprise a heterologous signal sequence operably linked to the Amb a1 allergen-encoding sequence.

- 24. (Currently Amended) The polynucleotide <u>composition</u> vaccine of claim 23, wherein the heterologous signal sequence comprises a hemagglutinin A (HA) signal sequence.
- 25. (Currently Amended) The polynucleotide <u>composition</u> vaccine of claim <u>23</u> <u>22</u>, wherein at least one codon of the nucleic acid sequence encoding the Amb a1 allergen is modified from a wild type sequence of the Amb a1 allergen to an analogous human codon.

26. (Canceled)

27. (Currently Amended) A polynucleotide composition comprising:

a polynucleotide comprising a nucleic acid sequence encoding plant allergen derived from a first phylum or first kingdom, wherein the nucleic acid sequence encoding the plant allergen is modified by deletion of a native signal sequence; and

an immunomodulatory nucleic acid molecule comprising the sequence 5'-cytosine-guanine-3' The polynucleotide vaccine composition of claim 26, wherein the nucleic acid sequence encoding the plant allergen antigen is further modified to include a heterologous signal sequence derived from a second phylum or second kingdom, wherein the signal sequence is operably linked to the antigenencoding sequence.

- 28. (Currently Amended) The polynucleotide vaccine composition of claim 27, wherein the heterologous signal sequence comprises a hemagglutinin A (HA) signal sequence.
- 29. (Currently Amended) The polynucleotide vaccine composition of claim 27 26, wherein at least one codon of the nucleic acid sequence encoding the plant allergen antigen is modified from a wild type sequence of the non-host species to an analogous codon of a host species.

Atty Dkt. No.: UCAL-203

USSN: 09/828,505

30. (Currently Amended) The polynucleotide vaccine composition of claim <u>27</u> 26, wherein the plant allergen antigen is Amb a1.

- 31. (Currently Amended) The polynucleotide vaccine composition of claim <u>27</u> <u>26</u>, wherein the immunomodulatory nucleic acid molecule comprises a sequence selected from the group consisting of 5'-rrcgyy-3', 5'-rycgyycg-3', 5'-rycgyycg-3' or 5'-(TCG)n-3'.
- 32. (Currently Amended) The polynucleotide vaccine composition of claim 27 26, wherein the immunomodulatory nucleic acid molecule comprises a the sequence AACGTT selected from the group consisting of: AACGTT, AGCGTT, GACGTT, GGCGTT, AACGTC, AGCGTC, GACGCT, GACGCT, GGCGCT, AACGCC, AGCGCC, GACGCC, GGCGCC, AACGCT, AGCGCT, GACGCT, GGCGCT, ATCGTT, ACCGTT, GCCGTT, ATCGTC, ACCGTC, GTCGTC, GCCGTC, ATCGCT, ACCGCT, GTCGCT, GCCGCT, ATCGCC, ACCGCC, GTCGCC, GCCGCC, AACGTTCG, AACGTTCG, GACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, AACGTTCG, ACCGTTCG, GCCGTTCG, ATCGTTCG, ACCGTTCG, GCCGTTCG, ATCGTTCG, ACCGTTCG, ATCGTTCG, ATCGTTCCG, ACCGTTCG, ACCGTTCG, ACCGTTCG, ATCGTTCG, ATCGTTCG, ATCGTTCG, ACCGTTCG, ACCGCTCG, ATCGCCCG, ACCGCTCG, ACCGCTCG, ACCGCTCG, ACCGCTCG, ATCGCCCG, ACCGCTCG, ACCGCTCG, ATCGCCCG, ACCGCTCG, ATCGCCCG, ACCGCTCG, ATCGCCCG, ACCGCCCG, ACCGCCCG, ATCGCCCCG, ACCGCTCG, ATCGCCCCG, ACCGCCCG, ACCGCTCG, ATCGCCCCG, ACCGCCCG, ACCGCTCG, ATCGCCCCG, ACCGCCCG, ACCGCTCG, ATCGCCCCG, ACCGCCCCG, ACCG

Please enter new claim 33, as shown below.

--33. (New) The method of claim 10, wherein the level of IgE specific for the plant allergen is reduced. --